HRP20120077T1 - Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora - Google Patents
Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora Download PDFInfo
- Publication number
- HRP20120077T1 HRP20120077T1 HR20120077T HRP20120077T HRP20120077T1 HR P20120077 T1 HRP20120077 T1 HR P20120077T1 HR 20120077 T HR20120077 T HR 20120077T HR P20120077 T HRP20120077 T HR P20120077T HR P20120077 T1 HRP20120077 T1 HR P20120077T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- substituents
- carbon atoms
- substituted
- independently selected
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title claims 3
- 230000001270 agonistic effect Effects 0.000 title 1
- 150000008641 benzimidazolones Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 claims abstract 40
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 31
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 21
- 150000001875 compounds Chemical class 0.000 claims abstract 19
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 125000003277 amino group Chemical group 0.000 claims abstract 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 14
- 125000002947 alkylene group Chemical group 0.000 claims abstract 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 10
- 125000004429 atom Chemical group 0.000 claims abstract 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000006549 dyspepsia Diseases 0.000 claims 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010030216 Oesophagitis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000006881 esophagitis Diseases 0.000 claims 2
- 230000030135 gastric motility Effects 0.000 claims 2
- 208000029493 gastroesophageal disease Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- -1 hydroxytetrahydropyranyl Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 230000036269 ulceration Effects 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- SOPZQKVIRRZVRV-UHFFFAOYSA-N 6-fluoro-n-[[1-[(4-hydroxyoxan-4-yl)methyl]piperidin-4-yl]methyl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound O=C1N(C(C)C)C2=CC=C(F)C=C2N1C(=O)NCC(CC1)CCN1CC1(O)CCOCC1 SOPZQKVIRRZVRV-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OMZWFGGPQLRSMV-UHFFFAOYSA-N n-[[1-[(4-hydroxyoxan-4-yl)methyl]piperidin-4-yl]methyl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound O=C1N(C(C)C)C2=CC=CC=C2N1C(=O)NCC(CC1)CCN1CC1(O)CCOCC1 OMZWFGGPQLRSMV-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50014403P | 2003-09-03 | 2003-09-03 | |
PCT/IB2004/002741 WO2005021539A1 (en) | 2003-09-03 | 2004-08-20 | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120077T1 true HRP20120077T1 (hr) | 2012-02-29 |
Family
ID=34272920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120077T HRP20120077T1 (hr) | 2003-09-03 | 2012-01-23 | Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora |
Country Status (40)
Country | Link |
---|---|
US (2) | US7776885B2 (da) |
EP (1) | EP1664036B1 (da) |
JP (1) | JP3983269B1 (da) |
KR (1) | KR100738784B1 (da) |
CN (1) | CN100482659C (da) |
AP (1) | AP2184A (da) |
AR (1) | AR045552A1 (da) |
AT (1) | ATE539077T1 (da) |
AU (1) | AU2004268840B9 (da) |
BR (1) | BRPI0414105B8 (da) |
CA (1) | CA2537127C (da) |
CR (1) | CR8267A (da) |
CY (1) | CY1112321T1 (da) |
DK (1) | DK1664036T3 (da) |
EA (1) | EA009457B1 (da) |
EC (1) | ECSP066407A (da) |
ES (1) | ES2377484T3 (da) |
GE (1) | GEP20084527B (da) |
GT (1) | GT200400174A (da) |
HK (1) | HK1093338A1 (da) |
HR (1) | HRP20120077T1 (da) |
IL (3) | IL173705A (da) |
IS (1) | IS8289A (da) |
MA (1) | MA28021A1 (da) |
MX (1) | MXPA06002550A (da) |
NL (1) | NL1026959C2 (da) |
NO (1) | NO20061519L (da) |
OA (1) | OA13248A (da) |
PA (1) | PA8610601A1 (da) |
PE (1) | PE20050874A1 (da) |
PL (1) | PL1664036T3 (da) |
PT (1) | PT1664036E (da) |
RS (1) | RS20060145A (da) |
SI (1) | SI1664036T1 (da) |
TN (1) | TNSN06073A1 (da) |
TW (1) | TW200510332A (da) |
UA (1) | UA86204C2 (da) |
UY (1) | UY28496A1 (da) |
WO (1) | WO2005021539A1 (da) |
ZA (1) | ZA200601324B (da) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
US7728006B2 (en) | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
MXPA06014486A (es) * | 2004-06-15 | 2007-03-01 | Pfizer | Derivados de acido carboxilico de bencimidazolona. |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
EP1807422B1 (en) | 2004-11-05 | 2009-09-02 | Theravance, Inc. | 5-ht4 receptor agonist compounds |
US7396933B2 (en) | 2004-11-05 | 2008-07-08 | Theravance, Inc. | Quinolinone-carboxamide compounds |
ATE469897T1 (de) | 2004-12-22 | 2010-06-15 | Theravance Inc | Indazolcarbonsäureamidverbindungen |
EP1856110B1 (en) | 2005-02-22 | 2011-06-22 | Pfizer Inc. | Oxyindole derivatives as 5ht4 receptor agonists |
BRPI0608392A2 (pt) | 2005-03-02 | 2009-12-29 | Theravance Inc | compostos de quinolinona como agonistas do receptor 5-ht4 |
EP1861377B1 (en) * | 2005-03-15 | 2010-12-29 | Pfizer, Inc. | Benzimidazolone derivatives as cb2 receptor ligands |
MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
JP5086248B2 (ja) * | 2005-06-07 | 2012-11-28 | セラヴァンス, インコーポレーテッド | 5−ht4受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物 |
ES2391107T3 (es) | 2005-09-30 | 2012-11-21 | Glaxo Group Limited | Compuestos que tienen actividad en el receptor M1 y sus usos en medicina |
JP5209479B2 (ja) * | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | M1受容体にて活性を有するベンゾイミダゾロン類 |
US8283364B2 (en) * | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
EP1984027B1 (en) * | 2006-01-24 | 2015-12-30 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
US20080318964A1 (en) * | 2007-06-19 | 2008-12-25 | Protia, Llc | Deuterium-enriched eszopiclone |
GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
JP5836280B2 (ja) | 2009-11-06 | 2015-12-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥/多動性障害(adhd)の治療方法 |
JP5901528B2 (ja) | 2009-11-06 | 2016-04-13 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 線維筋痛症候群の治療方法 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
MX343165B (es) * | 2010-02-12 | 2016-10-26 | Raqualia Pharma Inc | Agonistas del receptor 5-ht4 para el tratamiento de demencia. |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
WO2012074721A2 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of serotonin receptor antagonists by microinjection systems |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
WO2017093890A1 (en) * | 2015-11-30 | 2017-06-08 | Piramal Enterprises Limited | Clobazam tablet formulation and process for its preparation |
KR20220054211A (ko) * | 2020-10-23 | 2022-05-02 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체 화합물을 포함하는 구강붕해정 및 이의 제조방법 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US63716A (en) * | 1867-04-09 | Improved cheery stoner | ||
CH566987A5 (da) * | 1972-04-21 | 1975-09-30 | Ciba Geigy Ag | |
US3945953A (en) * | 1972-04-21 | 1976-03-23 | Ciba-Geigy Corporation | ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use |
DE3336024A1 (de) * | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0522914A1 (fr) * | 1991-06-27 | 1993-01-13 | Synthelabo | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
TW252206B (da) * | 1993-09-01 | 1995-07-21 | Philips Electronics Nv | |
IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU9309898A (en) | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
US6420410B1 (en) | 1998-11-24 | 2002-07-16 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |
TW570920B (en) * | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
JPWO2002053568A1 (ja) * | 2000-12-28 | 2004-05-13 | 持田製薬株式会社 | スピロ結合を有する三環系化合物を有効成分とするコレステロール生合成阻害剤 |
SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
MXPA06014486A (es) | 2004-06-15 | 2007-03-01 | Pfizer | Derivados de acido carboxilico de bencimidazolona. |
MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2004
- 2004-08-20 GE GEAP20049270A patent/GEP20084527B/en unknown
- 2004-08-20 BR BRPI0414105A patent/BRPI0414105B8/pt not_active IP Right Cessation
- 2004-08-20 DK DK04744319.7T patent/DK1664036T3/da active
- 2004-08-20 EP EP04744319A patent/EP1664036B1/en active Active
- 2004-08-20 OA OA1200600069A patent/OA13248A/en unknown
- 2004-08-20 AP AP2006003536A patent/AP2184A/xx active
- 2004-08-20 EA EA200600327A patent/EA009457B1/ru not_active IP Right Cessation
- 2004-08-20 SI SI200431820T patent/SI1664036T1/sl unknown
- 2004-08-20 CA CA2537127A patent/CA2537127C/en active Active
- 2004-08-20 AT AT04744319T patent/ATE539077T1/de active
- 2004-08-20 PT PT04744319T patent/PT1664036E/pt unknown
- 2004-08-20 UA UAA200602293A patent/UA86204C2/uk unknown
- 2004-08-20 PL PL04744319T patent/PL1664036T3/pl unknown
- 2004-08-20 RS YUP-2006/0145A patent/RS20060145A/sr unknown
- 2004-08-20 AU AU2004268840A patent/AU2004268840B9/en not_active Ceased
- 2004-08-20 CN CNB2004800252755A patent/CN100482659C/zh not_active Expired - Fee Related
- 2004-08-20 MX MXPA06002550A patent/MXPA06002550A/es active IP Right Grant
- 2004-08-20 KR KR1020067004335A patent/KR100738784B1/ko active IP Right Grant
- 2004-08-20 WO PCT/IB2004/002741 patent/WO2005021539A1/en active Application Filing
- 2004-08-20 JP JP2006525197A patent/JP3983269B1/ja active Active
- 2004-08-20 ES ES04744319T patent/ES2377484T3/es active Active
- 2004-08-31 PE PE2004000831A patent/PE20050874A1/es not_active Application Discontinuation
- 2004-09-01 AR ARP040103133A patent/AR045552A1/es not_active Application Discontinuation
- 2004-09-02 UY UY28496A patent/UY28496A1/es not_active Application Discontinuation
- 2004-09-02 PA PA20048610601A patent/PA8610601A1/es unknown
- 2004-09-02 GT GT200400174A patent/GT200400174A/es unknown
- 2004-09-02 US US10/933,629 patent/US7776885B2/en active Active
- 2004-09-02 TW TW093126507A patent/TW200510332A/zh unknown
- 2004-09-03 NL NL1026959A patent/NL1026959C2/nl not_active IP Right Cessation
-
2006
- 2006-02-09 IS IS8289A patent/IS8289A/is unknown
- 2006-02-13 IL IL173705A patent/IL173705A/en not_active IP Right Cessation
- 2006-02-14 ZA ZA200601324A patent/ZA200601324B/en unknown
- 2006-03-02 CR CR8267A patent/CR8267A/es not_active Application Discontinuation
- 2006-03-03 EC EC2006006407A patent/ECSP066407A/es unknown
- 2006-03-03 MA MA28851A patent/MA28021A1/fr unknown
- 2006-03-03 TN TNP2006000073A patent/TNSN06073A1/en unknown
- 2006-04-03 NO NO20061519A patent/NO20061519L/no not_active Application Discontinuation
- 2006-12-21 HK HK06114049.6A patent/HK1093338A1/xx not_active IP Right Cessation
-
2010
- 2010-05-06 IL IL205600A patent/IL205600A0/en unknown
- 2010-05-06 IL IL205599A patent/IL205599A0/en unknown
- 2010-07-07 US US12/831,713 patent/US20100273794A1/en not_active Abandoned
-
2012
- 2012-01-23 HR HR20120077T patent/HRP20120077T1/hr unknown
- 2012-02-06 CY CY20121100124T patent/CY1112321T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120077T1 (hr) | Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora | |
US11623921B2 (en) | Indole carboxamide compounds | |
CA2569654A1 (en) | Benzimidazolone carboxylic acid derivatives | |
CA2615611A1 (en) | Indazole derivatives | |
DE69633245T2 (de) | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation | |
CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity | |
CA2598536A1 (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
PT1704145E (pt) | Inibidores de quinase seletivos | |
RU2006124518A (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
JP2005510476A (ja) | 抗炎症剤として有用なスピロ−ヒダントイン化合物 | |
HRP20100153T1 (hr) | Antagonisti kemokin receptora | |
JP2018522034A (ja) | ムスカリン様アゴニスト | |
JP2009502770A5 (da) | ||
KR20140135954A (ko) | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 | |
JP2012507525A5 (da) | ||
CA2598516A1 (en) | Benzisoxazole derivatives | |
EP2934536B1 (en) | FACTOR IXa INHIBITORS | |
WO2020017569A1 (ja) | T型カルシウムチャネル阻害剤 | |
JPH01128970A (ja) | 新規複素環誘導体 | |
CA2421936A1 (en) | (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists | |
AU2016341259B2 (en) | Pyridone derivatives and their use as kinase inhibitors | |
JPWO2005030722A1 (ja) | N−置換−n−(4−ピペリジニル)アミド誘導体 | |
AU2004201666C1 (en) | 4-Imidazolin-2-one compounds | |
KR20230127271A (ko) | 헤테로시클릭 화합물 및 기생충성 질환을 위한 그의용도 | |
JP2000080081A (ja) | 1―〔(1―置換―4―ピペリジニル)メチル〕―4―ピペリジン誘導体及びそれを含有する医薬組成物 |